First, the magnitude of overall benefit of anti-PD1 therapy in cutaneous sarcomas that we observed compares favorably to other cutaneous malignancies such as melanoma in which this agent class has clearly become a preferred first line treatment option. The gene discussed is PDCD1; the disease is melanoma.